EU/3/00/013

Table of contents

About

On 29 December 2000, orphan designation (EU/3/00/013) was granted by the European Commission to Laxdale Ltd., United Kingdom, for ethyl eicosopentaenoate for the treatment of Huntington's disease. The name of the sponsor has since changed to Amarin Neuroscience Ltd.

Key facts

Active substance
Ethyl Eicosapentaenoate
Disease / condition
Treatment of Huntington’s disease
Date of first decision
29/12/2000
Outcome
Positive
EU designation number
EU/3/00/013

Sponsor's contact details

Amarin Neuroscience Ltd
Kings Park House
Laurelhill Business Park
STIRLING FK7 9JQ
United Kingdom
Telephone: +44 17 86 47 60 00
Telefax: +44 17 86 47 31 37
E-mail: admin@amarin-neuro.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

Related content

How useful was this page?

Add your rating